Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEPADINA AND SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tepadin A (thiotepa) is an alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death. It is cell cycle phase-nonspecific.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment of adenocarcinoma of the breast,Treatment of adenocarcinoma of the ovary,Palliative treatment of superficial papillary carcinoma of the urinary bladder,Conditioning regimen prior to allogeneic or autologous hematopoietic progenitor cell transplantation (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
6.25 mg/m2 (based on ideal body weight) intravenously over 2 hours every 6 hours for 16 doses (total dose 100 mg/m2) as part of conditioning regimen prior to hematopoietic stem cell transplantation.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life: 1.5–3.5 hours; clinically, the short half-life allows high-intensity dosing with stem cell support
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Primarily metabolized by cytochrome P450 enzymes, including CYP2B6 and CYP3A4, via oxidative desulfuration to active metabolites (e.g., tepa). Also undergoes glutathione conjugation.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily renal; approximately 60-70% of the dose is excreted unchanged in urine within 24 hours; minor fecal elimination (<10%)
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Minimal (<10%); primarily albumin
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.3–0.5 L/kg; indicates limited extravascular distribution
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral: approximately 75% (variable, 30-100%); intravenous: 100%
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific dose adjustments are provided for renal impairment. Use with caution in patients with renal impairment due to potential for nephrotoxicity from the drug or its metabolites; monitor renal function closely.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific dose adjustments are provided for hepatic impairment based on Child-Pugh score. Use with caution in patients with hepatic impairment; monitor liver function tests closely.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Children and adolescents: Same dose as adults (6.25 mg/m2 intravenously over 2 hours every 6 hours for 16 doses), based on ideal body weight. Safety and efficacy in neonates and infants have not been established.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
No specific dose adjustments recommended for elderly patients. Use with caution due to higher likelihood of decreased renal and hepatic function, and monitor for increased toxicity.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
WARNING: THIOTEPA IS HIGHLY TOXIC TO BONE MARROW. SEVERE MYELOSUPPRESSION, INCLUDING DEATH, MAY OCCUR. THIOTEPA IS CARCINOGENIC AND MUTAGENIC. IT SHOULD BE ADMINISTERED ONLY BY PHYSICIANS EXPERIENCED IN CANCER CHEMOTHERAPY.
None
Bone marrow suppression: Monitor blood counts frequently; dose adjustments may be necessary.,Carcinogenicity: Long-term use increases risk of secondary malignancies (e.g., myelodysplastic syndrome, acute leukemia).,Mutagenicity: Can cause chromosomal damage; use contraception during therapy.,Renal and hepatic impairment: Dose adjustment may be needed.,Hemorrhagic cystitis: Adequate hydration and frequent voiding recommended; monitor for hematuria.,Embryo-fetal toxicity: Can cause fetal harm; avoid pregnancy.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to thiotepa or any component of the formulation,Severe bone marrow depression (e.g., leukopenia, thrombocytopenia)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions. Maintain adequate hydration. Avoid grapefruit juice due to potential CYP3A4 interaction. Advise small, frequent meals to manage nausea.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
TEPADINA is a known teratogen in animals and is presumed to cause fetal harm when administered to pregnant women. Based on its mechanism of action as an alkylating agent, there is a high risk of teratogenicity, including congenital malformations and fetal demise, particularly during the first trimester. In the second and third trimesters, exposure may lead to fetal growth restriction, myelosuppression, or long-term developmental effects.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
There are no data on the presence of TEPADINA in human milk, its effects on the breastfed infant, or its effects on milk production. Due to the potential for serious adverse reactions in nursing infants, including myelosuppression and carcinogenicity, breastfeeding should be discontinued during treatment and for at least 2 weeks after the last dose.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No specific pharmacokinetic data are available for dosing adjustments in pregnancy. However, due to physiological changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism), careful monitoring for toxicity and efficacy is warranted. No standard dose adjustment is recommended; dosing should be based on therapeutic drug monitoring if available and clinical response.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
TEPADINA AND SODIUM CHLORIDE is used as a conditioning agent prior to hematopoietic stem cell transplantation (HSCT). Administer via intravenous infusion over 1-2 hours. Monitor for infusion reactions (bronchospasm, urticaria) and have resuscitation equipment available. Pre-medicate with anticonvulsants (e.g., phenytoin) to prevent seizure due to CNS toxicity. Observe for hepatotoxicity, especially veno-occlusive disease (VOD), and consider defibrotide prophylaxis. Adjust dose for renal impairment (Cr Cl < 60 m L/min). Use with caution in patients with pre-existing hepatic dysfunction.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is used to prepare your body for a stem cell transplant.,You will receive this drug intravenously (through a vein) in the hospital.,Common side effects include nausea, vomiting, diarrhea, and mouth sores.,You may experience temporary hair loss and skin rash.,Report any signs of infection (fever, chills), bleeding, or unusual bruising immediately.,Avoid driving or operating machinery if you feel dizzy or sleepy.,Do not receive live vaccines during treatment.,Use effective contraception during and for at least 6 months after treatment.,Drink plenty of fluids unless advised otherwise.,Inform your doctor if you have liver or kidney disease.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEPADINA AND SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
TEPADINA AND SODIUM CHLORIDE is a Electrolyte that works by Tepadin A (thiotepa) is an alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death. It is cell cycle phase-nonspecific.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEPADINA AND SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEPADINA AND SODIUM CHLORIDE is: 6.25 mg/m2 (based on ideal body weight) intravenously over 2 hours every 6 hours for 16 doses (total dose 100 mg/m2) as part of conditioning regimen prior to hematopoietic stem cell transplantation.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining TEPADINA AND SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. TEPADINA AND SODIUM CHLORIDE is classified as Category A/B. TEPADINA is a known teratogen in animals and is presumed to cause fetal harm when administered to pregnant women. Based on its mechanism of action as an alkylating agent, there is . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.